NeOnc Technologies

News

NeOnc Technologies' founder, chief executive and chief scientific officer Thomas Chen

NeOnc Technologies has another go at a Nasdaq listing

US biotech NeOnc Technologies has applied to list on the Nasdaq as it advances a portfolio of drugs to treat diseases affecting the CNS.

News

Metagenomi prices IPO and NeOnc joins list of hopefuls

Gene editing start-up Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings, in another sign that investor interes

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks